Kala Pharmaceuticals Announces Eysuvis Now Covered on UnitedHealthcare Commercial and Cigna Medicare

Kala Pharmaceuticals announced that UnitedHealthcare, one of the largest commercial health care plans in the United States covering approximately 13 million people, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022. Eysuvis now has coverage for approximately 118 million people, or 70% of all commercial patients.

Also today, Kala announced that Cigna Medicare has added Eysuvis as a preferred brand effective February 2022, adding an additional 1.9 million Medicare recipients. Eysuvis now has Medicare preferred coverage for select plans with Express Scripts, Prime Therapeutics and Cigna. Total Eysuvis Medicare coverage is now approximately 7.1 million people, or 15% of all Medicare recipients.

“Today’s announcement marks significant progress toward our goal of expanding access to Eysuvis for the millions of people who suffer from dry eye disease, including dry eye flares,” said Todd Bazemore, President and Chief Operating Officer of Kala Pharmaceuticals. “We look forward to continuing to engage with other commercial and Medicare Part D health plans as we execute on our goal of providing broad market access to Eysuvis for eye care professionals and their patients.”

Eysuvis became commercially available in January 2021 as the first and only FDA-approved medicine for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease.